Replies to post #11194 on DNAprint Genomics (DNAG)

[gunnabeoneday]

Frog:

thanks for the feedback.

Couple of things come to mind:
1) Doesn't BC have a greater reach than ORCH in distributing tests (vrs administering them)? I'm very familiar with ORCH and am invested in them also. I don't know much about BC.
2) If Retinome falls under the DNAWitness umbrella, do you believe that BC would still be entitled to execute this option?
3) As I understand the option, if a higher bidder steps in, BC would have the right to match that bid and retain rights. Correct?
4) If it's true about BC owning the option, then by leaving the ORCH partnership listing and related option PR on their website, DNAP is misleading the investment community and all potential customers as well. Agree?
5) You said that if BC passed on their option for DNAP's first product, then the option would no longer be an issue for subsequent products (Ovanome and Statinome). I didn't infer that from the PR......Can you elaborate?
6) Would ovanome be exempt from the option due to Univ. of Miami's involvement?

Thanks.

[1USGrant]

Frog...Was this post just your opinion or can you back it up with any facts? You stated it like it was factual, but hey I think it was just your opinion......

[Gcbr]

Frog---I could not disagree more. I have noticed how fast the
company changed to saying they were using the BC machine instead of an ORCH machine. BC has the money to deal---they will say yes or no very quickly. That will free DNAP up to move off the dime.

Take Care
Arch